Small-molecule inhibitors of HIV-induced receptor downmodulation
HIV 诱导的受体下调的小分子抑制剂
基本信息
- 批准号:8052156
- 负责人:
- 金额:$ 35.63万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2010
- 资助国家:美国
- 起止时间:2010-05-01 至 2012-04-30
- 项目状态:已结题
- 来源:
- 关键词:Acquired Immunodeficiency SyndromeAddressAdverse effectsAffectAgreementAnti-Retroviral AgentsAntiviral AgentsAntiviral TherapyBiological AssayBiological AvailabilityCD4 AntigensCaliforniaCellsCommitDevelopmentFamilyFlow CytometryFoundationsGenesHIVHIV InfectionsHealthHumanHuman VirusInfectionInhibitory Concentration 50InterventionLaboratoriesLeadLegal patentLettersLibrariesLicensingMarketingMediatingMethodsMorphologic artifactsMulti-Drug ResistanceOralPathogenesisPeripheral Blood Mononuclear CellPharmaceutical ChemistryPharmaceutical PreparationsPharmacologic SubstancePhasePhorbol EstersPhysiologicalPrincipal InvestigatorProductionProteinsProtocols documentationResearchResistanceRightsSalesScreening procedureSignal TransductionSpecificitySystemTestingTherapeuticTherapeutic IndexUniversitiesValidationViralVirusVirus DiseasesVirus ReceptorsWorkantiretroviral therapybasebiosafety level 2 facilitycytotoxicitycytotoxicity testdrug discoverydrug resistant virusimprovedin vivoinhibitor/antagonistlead seriesnovelnovel strategiesparticlepre-clinicalprogramspublic health relevancereceptorresistant strainsmall moleculesmall molecule librariessuccessvirology
项目摘要
DESCRIPTION (provided by applicant): Multiple lines of evidence suggest that down-modulation of the viral receptor in HIV- infected cells is an essential function modulating pathogenesis in vivo. We have previously performed proof-of-concept studies demonstrating that interference with this function results in the production of non-infectious particles unable to replicate in permissive cells. Here we propose to screen a library of small molecules to identify inhibitors of CD4 down-modulation. We will use a simple screening assay that recapitulates physiological conditions and use natural target cells of infection. We propose the following aims: (1) to optimize an assay for CD4 down-modulation in HIV-infected PBMC; (2) to screen a library of 20,000 drug-like compounds, and; (3) to validate and characterize the potency, cytotoxicity and specificity of hits. Studies will be implemented to optimize screening conditions, reduce assay-to-assay variability and perform statistical analysis to set thresholds for hit identification. False positives and artifacts will be discriminated in secondary assays, and true hit compounds will be prioritized based on potency, specificity, and lack of cytotoxicity. Preliminary studies will be performed to validate the mechanism of action and test the compounds antiviral activity with laboratory adapted HIV strains and primary isolates. Success in this Phase I application is defined as the milestone identification of one or more bona fide lead series of drug-like compounds with IC50s below 5 5M in HIV replication assays and minimal cytotoxicity (CC50 10-fold greater than IC50). Lead compounds with these profiles will be optimized for potency, specificity and bioavailability in a Phase II project aimed at advancing the preclinical development of these compounds to support human trials. These studies will constitute the foundation of a drug discovery program that may result in the characterization of first-in-class drugs of a novel family of antiretrovirals. PUBLIC HEALTH RELEVANCE: As of the end of 2007, 33 million people worldwide are infected with HIV. Despite advances in antiretroviral therapies, side-effects and the emergence of viruses resistant to currently available drugs pose important problems for the treatment of HIV. We propose to identify and characterize antiretroviral compounds that block HIV through a novel mechanism. These unique compounds could be used for the treatment of HIV infection.
描述(由申请方提供):多条证据表明,HIV感染细胞中病毒受体的下调是体内调节发病机制的基本功能。我们之前已经进行了概念验证研究,证明干扰这种功能会导致产生无法在允许细胞中复制的非感染性颗粒。在这里,我们建议筛选一个小分子库,以确定抑制剂的CD 4下调。我们将使用一个简单的筛选试验,概括生理条件和使用天然的感染靶细胞。我们提出以下目标:(1)优化HIV感染的PBMC中CD 4下调的测定法;(2)筛选20,000种药物样化合物的库;(3)验证和表征命中的效力、细胞毒性和特异性。将进行研究,以优化筛选条件,降低检测试剂盒间变异性,并进行统计分析,以设定命中识别的阈值。假阳性和伪影将在二次测定中进行区分,真正的命中化合物将根据效力、特异性和缺乏细胞毒性进行优先排序。将进行初步研究,以验证作用机制,并测试化合物的抗病毒活性与实验室适应的艾滋病毒株和主要分离株。在这一阶段I应用的成功被定义为一个或多个真正的铅系列的药物样化合物的里程碑识别与IC 50低于5 5 M在HIV复制试验和最小的细胞毒性(CC 50 10倍大于IC 50)。具有这些特征的先导化合物将在旨在推进这些化合物的临床前开发以支持人体试验的II期项目中针对效力、特异性和生物利用度进行优化。这些研究将构成药物发现计划的基础,该计划可能导致抗逆转录病毒药物新家族的一流药物的表征。公共卫生相关性:截至2007年底,全世界有3 300万人感染艾滋病毒。尽管在抗逆转录病毒疗法方面取得了进展,但副作用和出现对现有药物具有抗药性的病毒给艾滋病毒的治疗带来了重大问题。我们建议通过一种新的机制来鉴定和表征阻断HIV的抗逆转录病毒化合物。这些独特的化合物可用于治疗HIV感染。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JUAN LAMA其他文献
JUAN LAMA的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JUAN LAMA', 18)}}的其他基金
Inhibitors of HIV-induced downregulation of HLA class I
HIV 诱导的 I 类 HLA 下调的抑制剂
- 批准号:
8410864 - 财政年份:2012
- 资助金额:
$ 35.63万 - 项目类别:
Inhibitors of HIV-induced downregulation of HLA class I
HIV 诱导的 I 类 HLA 下调的抑制剂
- 批准号:
8465183 - 财政年份:2012
- 资助金额:
$ 35.63万 - 项目类别:
Targeting HIV-1 Envelope glycoprotein incorporation
靶向 HIV-1 包膜糖蛋白掺入
- 批准号:
7685833 - 财政年份:2009
- 资助金额:
$ 35.63万 - 项目类别:
Small-molecule inhibitors of HIV-induced receptor downmodulation
HIV 诱导的受体下调的小分子抑制剂
- 批准号:
7754471 - 财政年份:2009
- 资助金额:
$ 35.63万 - 项目类别:
Fusion assay of the HIV-induced CD4 down-modulation
HIV 诱导的 CD4 下调的融合测定
- 批准号:
7140590 - 财政年份:2005
- 资助金额:
$ 35.63万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 35.63万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 35.63万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 35.63万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 35.63万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 35.63万 - 项目类别:
Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 35.63万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 35.63万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 35.63万 - 项目类别:
EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 35.63万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 35.63万 - 项目类别:
Research Grant